Burjeel Holdings, a leading super-specialty healthcare services provider in the MENA region, has signed a Memorandum of Understanding (MoU) with Egypt’s Ministry of Health in order to strengthen their healthcare collaboration.
The partnership intends to expand access to advanced oncology care across Africa, focusing on developing a comprehensive Bone Marrow Transplant (BMT) Program.
This initiative will be spearheaded by Burjeel Medical City (BMC), the flagship facility of Burjeel Holdings, supported by Burjeel Cancer Institute, the largest integrated cancer care network in the UAE.
As part of the commitment to improving patient outcomes, the collaboration will develop a dedicated strategy to address and reduce the backlog of BMT patients in Egypt, ensuring timely access to life-saving procedures.
Under this initiative, Burjeel Holdings will leverage the expertise from its highly successful BMT program at BMC to establish a world-class transplant unit in Egypt. The program will integrate proven protocols, advanced treatment methodologies, and multidisciplinary clinical approaches to enhance patient care and improve transplant success rates.
Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, said that, “We are honored to collaborate with the Ministry of Health, Egypt, in driving transformative changes in oncology care. Through strategic initiatives in training, research, and patient access, we look forward to making a meaningful impact in cancer treatment in Egypt.”
Comprehensive training for adult and pediatric BMT programs will be provided, empowering physicians, nurses, lab technicians, and support services in Egypt. The training will include hands-on experience in cutting-edge transplant techniques, post-transplant care, and multidisciplinary patient management, ensuring that local medical professionals are equipped with the latest advancements in BMT care.
Furthermore, the MoU paves the way for a research partnership between the Health Ministry and BMC, focusing on pioneering cancer treatments such as CAR-T cell therapy to advance Egypt’s capabilities in next-generation oncology solutions and innovative therapies.
In addition to BMT training, the partnership will extend specialized training to radiation oncology staff on advanced techniques, including stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) using the cutting-edge BrainLab system. To enhance diagnostic and precision medicine capabilities, staff will also receive training in molecular lab techniques, molecular pathology, and digital pathology, in collaboration with OncoHelix.
“This partnership with Burjeel Holdings underscores our commitment to enhancing healthcare accessibility and innovation in Egypt. By leveraging their expertise in oncology care, BMT program, and medical training, we aim to bring the highest cancer treatment standards to our patients,” noted HE Khaled Abdel Ghaffar, Deputy Prime Minister and Minister of Health and Population of Egypt.
